Skip to main content
INTENSITY THERAPEUTICS, INC. logo

INTENSITY THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · INTS ISIN · US45828J1034 US Manufacturing
Open in API
Filings indexed 222 across all filing types
Latest filing 2026-04-30 Annual Report
Country US United States of America
Listing US INTS

About INTENSITY THERAPEUTICS, INC.

https://www.intensitytherapeutics.com

Intensity Therapeutics, Inc. is a late-stage clinical company developing a novel intratumoral approach to treat solid tumor cancers. Its proprietary DfuseRx℠ platform technology facilitates the direct injection of therapeutic agents into tumors, enabling high drug absorption and dispersion. This "treat locally, act globally" method is designed to kill cancer cells in the injected tumor and simultaneously stimulate a systemic, personalized T-cell immune response against both the primary tumor and distant metastases. The company's lead product candidate, INT230-6, is advancing in late-stage clinical trials for multiple cancers, including sarcoma and breast cancer. The goal is to extend survival for patients with metastatic disease and prevent recurrence in presurgical settings.

Recent filings

Filing Released Lang Actions
ARS - INTENSITY THERAPEUTICS, INC. (0001567264) (Filer)
Annual Report
2026-04-30 English
8-K - INTENSITY THERAPEUTICS, INC. (0001567264) (Filer)
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated March 23, 2026. It announces an increase in the capacity of the company's existing at-the-market (ATM) offering program to $60 million. The document includes details about the offering agreement and the discretion of the company to issue shares under this program. It also attaches a legal opinion regarding the issuance and sale of shares. There are no financial statements or comprehensive financial data presented, nor is this a full annual or quarterly report. The content focuses on capital raising activities and financing updates. Therefore, this filing fits the category of Capital/Financing Update (CAP). The document length is 4772 characters, which is sufficient to contain substantive information about the financing update rather than just an announcement of a report publication or a regulatory filing. Hence, the classification is CAP with high confidence.
2026-03-23 English
424B5 - INTENSITY THERAPEUTICS, INC. (0001567264) (Filer)
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to an at-the-market (ATM) offering of common stock by Intensity Therapeutics, Inc. It updates and amends previous prospectus documents to increase the maximum aggregate gross sales price of common stock that may be offered. The document is focused on capital raising activities and financing terms, specifically the increase in the offering size under an existing sales agreement. It does not contain financial statements or detailed financial performance data, nor is it a full annual or quarterly report. It is not a regulatory filing for certification or a report publication announcement. The content clearly fits the category of Capital/Financing Update, which covers updates on company fundraising and financing activities.
2026-03-23 English
8-K Filing
Share Issue/Capital Change Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The key content is the announcement of a reverse stock split (1-for-25) of the company's common stock, effective February 18, 2026. This involves amendments to the certificate of incorporation and changes to stock structure. The document includes a Certificate of Amendment and a press release as exhibits. The nature of the filing is an announcement of a capital structure change, specifically a reverse stock split, which falls under the category of Share Issue/Capital Change (SHA). The document is not a full financial report, earnings release, or management discussion, but a regulatory announcement of a capital change event.
2026-02-13 English
S-8 Filing
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC by Intensity Therapeutics, Inc. Form S-8 is used to register securities to be offered under employee benefit plans, such as stock incentive plans. The text includes details about the registration of additional shares under the 2021 Stock Incentive Plan, references to prior Form S-8 filings, and incorporation by reference of other SEC filings. It is not a financial report, earnings release, proxy statement, or any other report type listed. It is a regulatory filing related to securities registration under the Securities Act of 1933. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length is substantial and contains detailed legal and regulatory information, confirming it is not a mere announcement but a full regulatory filing.
2026-01-23 English
FORM 4
Director's Dealing
2026-01-05 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.